Evaluate Safety and Efficacy of ABT-335 in Combination With Rosuvastatin Calcium in Subjects With Multiple Abnormal Lipid Levels in the Blood

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare the safety and efficacy of fenofibric acid (ABT-335) + rosuvastatin calcium combination therapy with ABT-335 and rosuvastatin calcium monotherapy in subjects with multiple abnormal lipid levels in the blood.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Abbott
• Treatments: Calcium; Calcium, Dietary; Fenofibric acid; Rosuvastatin Calcium

Criteria

Inclusion Criteria:

• Patients with mixed dyslipidemia

Exclusion Criteria:

• Subjects with unstable medical conditions or medical conditions considered inappropriate in a clinical trial.

• Patients who are taking certain medications or unstable dose of specific medications.

• Women who are pregnant or plan on becoming pregnant or women who are lactating.